Subhendu Karmakar

8PUBLICATIONS
21CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Organometallic chemistryBiomolecular modelling and designMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 04, 2026
A Cisplatin-Based Prodrug Inhibits Nucleotide Excision Repair Independently of Chromatin Accessibility to Overcome Resistance.

|Jan 18, 2024
Stepwise optimization of tumor-targeted dual-action platinum(iv)-gemcitabine prodrugs.

Alexander Kastner, Theresa Mendrina, Tomer Babu

|Nov 11, 2020
Platinum(IV)-Estramustine Multiaction Prodrugs Are Effective Antiproliferative Agents against Prostate Cancer Cells.

Subhendu Karmakar, Hana Kostrhunova, Tereza Ctvrtlikova

|May 20, 2020
Oxidation of cis-Diamminediacetato PtII with Hydrogen Peroxide Can Give Rise to Two Isomeric PtIV Products.

D Khattib, M Ishan, S Karmakar

|Mar 25, 2020
Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules.

Tomer Babu, Amrita Sarkar, Subhendu Karmakar

|Feb 06, 2020
Oxamusplatin: a cytotoxic Pt(ii) complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer.

Moumita Maji, Subhendu Karmakar, Ruturaj

Pageof 2

Frequent Collaborators

7 joint publications

Dan Gibson

3 joint publications

Tomer Babu

2 joint publications

Viktor Brabec

2 joint publications

Christian R Kowol